Star-studded warning on medication switching for epileptics

Share this article:
Star-studded warning on medication switching for epileptics
Star-studded warning on medication switching for epileptics
Lundbeck, Upsher-Smith, UCB and GlaxoSmithKline are among the sponsors of an epilepsy awareness campaign, featuring Heroes star Greg Grunberg, that warns of the dangers of medication switching.

Grunberg, whose son was diagnosed with epilepsy at age 7, previously partnered with the Epilepsy Foundation to create TalkAboutIt.org, a celeb-studded disease awareness website. New content on the site includes a segment on medication switching that's hosted by Aussie actor Jesse Spencer, who plays Dr. Chase on House.

“Not all epilepsy medications are the same,” says Spencer. “Make sure your prescribed medicine is what you bring home.”

Spencer's introduction cues up a video in which Grunberg recounts to a doctor specializing in epilepsy a time when he went to get his son's prescription refilled and was given a generic instead. His son began having seizures. The doctor, Brien J. Smith, MD of Henry Ford Hospital in Detroit, counsels that while nine in 10 epilepsy patients who are switched will be fine, there's no way of predicting who the other 10% will be.

Other sections of the unbranded site, designed by Day for Night, cover topics like first aid, lifestyle issues, employment, and advice for parents and friends of people with epilepsy.

Lundbeck makes Sabril for epilepsy, while UCB makes Vimpat and Keppra and GSK makes Lamictal.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...